임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
25건 표시
- 2상모집 예정· Malignant Neoplasm고형암 청소년 참가자를 대상으로 한 벨주티판 연구(MK-9999-01E/LIGHTBEAM-U01)
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
리드: 머크(MSD)
- 2상모집 예정· Recurrent Adenoid Cystic Carcinoma재발/전이성 선양낭종암 및 유두상 갑상선암에서의 Sacituzumab Tirumotecan (STRAP)
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
협력: 머크(MSD)
- 2상모집 예정· Anal Squamous Cell CarcinomaPhase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
협력: 머크(MSD)
- 2상모집 예정· Chronic Lymphocytic LeukemiaNemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
협력: 머크(MSD)
- 2상모집 예정· Urothelial Bladder CancerEnfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
협력: 머크(MSD)
- 2상모집 예정· Pulmonary Arterial HypertensionA Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
리드: 머크(MSD)
- 2상모집 예정· Prostate CancerSacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
협력: 머크(MSD)
- 2상모집 예정· Chronic Lymphocytic LeukaemiaA Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
리드: 머크(MSD)
- 2상모집 예정· Recurrent Mantle Cell LymphomaNemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
협력: 머크(MSD)
- 2상모집 예정· HPV-positive Oropharyngeal Squamous Cell CarcinomaRisk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
협력: 머크(MSD)
- 2상모집 예정· TNBC - Triple-Negative Breast CancerASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
협력: 머크(MSD)
- 2상모집 예정· Metastatic Triple Negative Breast CancersSac-TMT for Active TNBC Brain Metastases
협력: 머크(MSD)
- 2상모집 예정· Cervical Cancer by FIGO Stage 2018Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
협력: 머크(MSD)
- 2상모집 예정· Metastatic Pancreatic CancerOlaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
협력: 머크(MSD)
- 2상모집 예정· Primary GlioblastomaEvaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
협력: 머크(MSD)
- 2상모집 예정· Cervical AdenocarcinomaPembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
협력: 머크(MSD)
- 2상모집 예정· Non-small Cell Lung Cancer MetastaticT-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
협력: 머크(MSD)
- 2상모집 예정· Infections, CytomegalovirusEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
협력: 머크(MSD)
- 2상모집 예정· Advanced Non-squamous Non-small-cell Lung CancerEfficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
협력: 머크(MSD)
- 2상모집 예정· Locally Advanced Non-small Cell Lung CancerPembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
협력: 머크(MSD)
- 2상모집 예정· High Risk Superficial Upper Urinary Tract Transitional Cell CarcinomaPembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.